Device Trial Radar · NCT04452149
Algorithm Using LINQ Sensors for Evaluation And Treatment of Heart Failure
Last checked: Nov 21, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
826
Actual
Start
Sep 3, 2020
Primary completion
Jun 2, 2025
Study completion Jun 2, 2025
Sponsor
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart FailurePublic (MDT)
- Sponsor type
- Industry
- First posted
- Jun 30, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The ALLEVIATE-HF study is a prospective, randomized, controlled, blinded, multi-site, interventional, investigational device exemption (IDE) pivotal study. The purpose of the study is to demonstrate the safety and efficacy of a patient management pathway that utilizes an integrated device diagnostic-based risk stratification algorithm to guide patient care in subjects with NYHA class II and III heart failure, and to demonstrate the safety of the Reveal LINQ™ system and procedure in the study population.
Conditions
- Heart Failure NYHA Class II
- Heart Failure NYHA Class III
Interventions
Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware downloadDevice
Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download.
Medication interventionOther
Risk status guided medication intervention.
Not Randomized to Device or Medication InterventionOther
No intervention was assigned due to not being randomized under the final version of the investigational plan
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of Patient Management Pathway - Proportion of PRN Medication Interventions With Associated PRN Medication Intervention Related Serious Adverse Events (SAEs)Time frame: From 6 weeks after installation of RAMware through the duration of follow-up for Intervention arm subjects, and from the conclusion of the 13-month randomized period through the duration of follow-up for Observation arm subjects, up to 3 years.
1 more outcomes with a free account
Locations
53 sites in 1 country. Site status is shown where the registry gives one.
Cardiovascular Associates of Mesa
Mesa, Arizona
52 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.